{"id":920717,"date":"2025-12-17T16:24:42","date_gmt":"2025-12-17T21:24:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/"},"modified":"2025-12-17T16:24:42","modified_gmt":"2025-12-17T21:24:42","slug":"abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/","title":{"rendered":"Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <b>Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <b><br \/>\n            <i>Breadth of Scientific Evidence: <\/i><br \/>\n          <\/b><br \/>\n          <i>The acceptance of<\/i><br \/>\n          <i>1 oral presentation, 5 digital oral<\/i><br \/>\n          <i>presentations and 16 posters reflect an expanding dataset for obefazimod, including additional efficacy, safety, and cytokine data from the Phase 3 ABTECT Induction Trials in moderate-to-severely active ulcerative colitis (UC)<\/i><\/p>\n<\/li>\n<li style=\"text-align:justify\">\n          <b><br \/>\n            <i>Novel Anti-Fibrotic Preclinical Findings:<\/i><br \/>\n          <\/b><br \/>\n          <i> Oral presentation on Saturday, February 21, 2026, \u201cObefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease,&#8221; will disclose new preclinical data addressing a critical complication in Crohn&#8217;s disease (CD)<\/i><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>PARIS, France \u2013 December 17, 2025 \u2013 10:05 pm CET<\/b> \u2013 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hgyZgPWzYYUzBx8nsVMAqpSdmCxnW2JkqgzknEQLm69Up6IJKmvGHt1sT7dd6r9TUx6RgU2auDJAw6-T9jcI6Q==\" rel=\"nofollow\" target=\"_blank\">Abivax SA<\/a> (Euronext Paris: FR0012333284 \u2013 ABVX \/ Nasdaq: ABVX) (\u201cAbivax\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company focused on developing therapeutics that harness the body\u2019s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced that 22 scientific abstracts detailing advancements in the understanding of obefazimod for the treatment of inflammatory bowel disease (IBD) will be presented at The European Crohn\u2019s and Colitis Organization\u2019s (ECCO) 21st Annual Congress taking place February 18-21, 2026 in Stockholm, Sweden.<\/p>\n<p align=\"justify\">\n        <b>Subgroup Analyses from Phase 3 ABTECT Induction Trials<\/b>\n      <\/p>\n<p align=\"justify\">The accepted abstracts, based on subgroup analyses from ABTECT Induction Trials, illustrate obefazimod\u2019s clinical activity across a wide range of patient subpopulations, demonstrate downregulation of pro-inflammatory cytokines (IL-17A, IL-6), and highlight early symptomatic improvement along with other clinically meaningful benefits. The data also reinforces obefazimod\u2019s favorable tolerability profile.<\/p>\n<p align=\"justify\">\n        <b>Obefazimod Shows First Evidence of Activity in Preclinical Fibrotic Models<\/b>\n      <\/p>\n<p align=\"justify\">The upcoming oral presentation on anti-fibrotic activity addresses a significant unmet medical need in IBD. Fibrosis, or the excessive formation of scar tissue, is a serious complication, particularly in patients with CD. This scarring can lead to strictures (narrowing of the intestine) that often necessitate surgery. To date, no efficacious anti-fibrotic treatment is available for IBD patients.<\/p>\n<p align=\"justify\">The objective of the preclinical study was to assess the anti-fibrotic effects of obefazimod in an in vitro fibrosis model using human small-intestinal fibroblasts and in an in vivo TNBS-colitis mouse model. The data from this study, titled \u201cObefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease,\u201d will be presented during the oral presentation session on Saturday, February 21, 2026.<\/p>\n<p align=\"justify\">\n        <b>Marc de Garidel, Chief Executive Officer of Abivax, said<\/b><br \/>\n        <i>\u201cWe are highly enthusiastic about the strong presence of obefazimod data at the 21st ECCO Congress, highlighting the impactful and robust data we have generated in inflammatory bowel disease. Presenting a total of 22 abstracts highlights the increasing depth of clinical understanding we have gained from the ABTECT Induction Trials in ulcerative colitis. This important data, along with the oral presentation highlighting the first evidence of anti-fibrotic activity in a preclinical model, demonstrates the potential for obefazimod to address a critical unmet need in IBD beyond inflammation.\u201d<\/i>\n      <\/p>\n<p align=\"justify\">\n        <b>Fabio Cataldi, MD, Chief Medical Officer of Abivax<\/b>, <b>added<\/b>, <i>\u201cIntestinal fibrosis is a major complication of Crohn\u2019s disease that is not fully addressed by current therapies. This often leads to debilitating symptoms and the need for resection surgery. We look forward to sharing these new insights on obefazimod\u2019s anti-fibrotic properties, alongside the expansive clinical data to demonstrate obefazimod\u2019s potential efficacy and favorable safety profile in ulcerative colitis, with the IBD scientific community in Stockholm.\u201d<\/i><\/p>\n<p>\n        <b>Obefazimod Data to be Presented: <\/b>\n      <\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;border-collapse:collapse\">\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Date &amp; Time <\/b>\n          <\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Session<\/b>\n          <\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Room<\/b>\n          <\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Abstract #<\/b>\n          <\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Title<\/b>\n          <\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Presenter<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"6\" style=\"width:732.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Oral Presentation<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Sat, Feb 21<br \/>08:40\u201308:50<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Holistic IBD Care &#8211; Session 10: Holistic Approach &#8211; Multidisciplinary Team<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Plenary Hall<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">OP30<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Obefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Silvio Danese, MD, PhD<\/p>\n<p>Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital<\/td>\n<\/tr>\n<tr>\n<td colspan=\"6\" style=\"width:732.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Digital Oral Presentations (DOP)<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>08:42\u201308:48<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">DOP Session 7: Clinical Trials II<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">A5<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">DOP057<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Obefazimod induction therapy for moderately to severely active ulcerative colitis: pooled analysis of inflammatory biomarkers from the two ABTECT Phase 3 double-blind, placebo-controlled induction trials<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Britta Siegmund, MD<\/p>\n<p>Medical Director of the Medical Department, Division of Gastroenterology, Infectiology and Rheumatology, Charite Universit\u00e4tsmedizin Berlin<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>09:00\u201309:06<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">DOP Session 7: Clinical Trials II<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">A5<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">DOP060<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Impact of baseline disease extent on efficacy of obefazimod in patients with moderately to severely active ulcerative colitis: pooled results from ABTECT-1 and ABTECT-2 Phase 3 trials<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Sonja Heeren, MD<\/p>\n<p>Gastroenterologist at LKH &#8211; Universit\u00e4tsklinikum der PMU Salzburg, Austria<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>09:06\u201309:12<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">DOP Session 7: Clinical Trials II<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">A5<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">DOP061<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Improvements in patient-reported, disease-specific and overall quality-of-life among patients with moderately to severely active UC treated with obefazimod induction therapy: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3 trials<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Filip Baert, MD, PhD<\/p>\n<p>Head of the Department of Gastroenterology at AZ Delta Hospital<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>17:51\u201317:57<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">DOP Session 12: Clinical Trials III<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">A5<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">DOP101<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Impact of baseline disease duration on the efficacy of once-daily oral obefazimod in moderately to severely active ulcerative colitis: week 8 results from the ABTECT-1 and ABTECT-2 Phase 3 trials<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Geert D\u2019Haens, MD, PhD<\/p>\n<p>Professor of Gastroenterology at Amsterdam University Medical Centers<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>17:57\u201318:03<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">DOP Session 12: Clinical Trials III<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">A5<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">DOP102<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Improvements in patient-reported fatigue among patients with moderately to severely active UC treated with obefazimod induction therapy: pooled results from the 8-week ABTECT-1 and ABTECT-2 Phase 3 trials<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Marla Dubinsky, MD<\/p>\n<p>Professor of Pediatrics and Medicine, Chief, Division of Pediatric Gastroenterology and Nutrition, Co-Director, Susan and Leonard Feinstein IBD Clinical Center, Mount Sinai Kravis Children\u2019s Hospital, Icahn School of Medicine Mount Sinai New York<\/td>\n<\/tr>\n<tr>\n<td colspan=\"6\" style=\"width:732.67px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <b>Posters<\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P0690<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Impact of concomitant corticosteroid use on efficacy and safety of obefazimod at week 8 in moderately to severely active UC<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Xavier Treton, MD, PhD<\/p>\n<p>Professor of Gastroenterology (MD, PhD), Paris Inflammatory Bowel Disease (IBD) Center, Centre Ambroise Pare-Hartmann, Neuilly, France<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P0694<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Pooled analysis of efficacy and safety of once-daily oral obefazimod in North American patients from the ABTECT Phase 3 induction trials<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Bruce E Sands, MD, MS<\/p>\n<p>Professor of Medicine, Icahn School of Medicine at Mount Sinai<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P0712<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Integrated summary of safety of obefazimod in Phase 3 ABTECT induction trials<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Ursula Seidler, MD<\/p>\n<p>Professor of Internal Medicine and Gastroenterology, Hepatology, and Endocrinology; Senior Attending Physician at Medizinische Hochschule Hannover<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P0713<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Improvements in patient-reported bowel urgency and nocturnal bowel movements among patients with moderately to severely active UC treated with obefazimod induction therapy<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Marla Dubinsky, MD<\/p>\n<p>Professor of Pediatrics and Medicine, Chief, Division of Pediatric Gastroenterology and Nutrition, Co-Director, Susan and Leonard Feinstein IBD Clinical Center, Mount Sinai Kravis Children\u2019s Hospital, Icahn School of Medicine Mount Sinai New York<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P0804<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Impact of prior inadequate response to advanced therapies on early symptomatic improvement with obefazimod induction in moderately to severely active UC<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Raja Atreya, MD<\/p>\n<p>Professor of Translational Immunology in IBD<br \/>Head of IBD Unit, Outpatient Clinic, Study Centre, University Hospital Erlangen<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P0862<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Continued efficacy improvement beyond induction with once-daily obefazimod: week 8\u201348 outcomes from the Phase 2b open-label maintenance study, stratified by prior advanced-therapy exposure<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Alessandro Armuzzi<\/p>\n<p>ECCO President-Elect; Professor of Gastroenterology; Director\/Leader of the IBD Unit and Co-Lead of the IBD Center, IRCCS Humanitas Research Hospital and Humanitas University, Milan, Italy<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P0868<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Obefazimod enhances miR-124 expression in blood and colon tissue and reduces IL-17A and IL-6 in serum of patients with moderate-to-severely active UC<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Britta Siegmund, MD<\/p>\n<p>Medical Director of the Medical Department, Division of Gastroenterology, Infectiology and Rheumatology, Charite Universit\u00e4tsmedizin Berlin<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P0892<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Impact of prior inadequate response to advanced therapy (ATIR) on the efficacy of obefazimod in patients with moderately to severely active UC<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Filip Baert, MD, PhD<\/p>\n<p>Head of the Department of Gastroenterology at AZ Delta Hospital<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P0894<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Impact of prior advanced therapy inadequate response by drug class on symptomatic improvement with obefazimod in patients with moderately to severely active UC<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Silvio Danese, MD, PhD<\/p>\n<p>Director of Gastroenterology and Gastrointestinal Endoscopy Unit at IRCCS San. Raffaele Hospital<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P0922<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Impact of obefazimod treatment on histologic and combined histologic-endoscopic outcomes in patients with moderately to severely active UC<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Fernando Magro, MD, PhD<\/p>\n<p>ECCO President, Consultant in Gastroenterology and Director of the Clinical Pharmacology Unit, at the S\u00e3o Jo\u00e3o University Hospital in Porto, Portugal<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P0923<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Early symptomatic improvement with obefazimod in patients with moderately to severely active UC<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Alessandro Armuzzi, MD, PhD<\/p>\n<p>ECCO President-Elect; Professor of Gastroenterology; Director\/Leader of the IBD Unit and Co-Lead of the IBD Center, IRCCS Humanitas Research Hospital and Humanitas University, Milan, Italy<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P0928<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Improvements in patient-reported work productivity and activity impairment among patients with moderately to severely active UC treated with obefazimod induction therapy<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Britta Siegmund, MD<\/p>\n<p>Medical Director of the Medical Department, Division of Gastroenterology, Infectiology and Rheumatology, Charite Universit\u00e4tsmedizin Berlin<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P0952<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Impact of baseline Mayo endoscopic subscore on the efficacy of once-daily oral obefazimod in moderately to severely active UC<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Laurent Peyrin-Biroulet, MD, PhD<\/p>\n<p>Professor of Gastroenterology, specialist in inflammatory bowel disease at Nancy University Hospital, France<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P1048<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Impact of age on the efficacy and safety of once-daily oral obefazimod in moderately to severely active UC<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Fernando Magro, MD, PhD<\/p>\n<p>ECCO President, Consultant in Gastroenterology and Director of the Clinical Pharmacology Unit, at the S\u00e3o Jo\u00e3o University Hospital in Porto, Portugal<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P1077<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Impact of baseline body mass index (BMI) on efficacy of obefazimod in patients with moderately to severely active UC<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">David T Rubin, MD<\/p>\n<p>Professor of Medicine and Chief, Gastroenterology, Hepatology and Nutrition at The University of Chicago<\/td>\n<\/tr>\n<tr>\n<td style=\"width:113.87px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Fri, Feb 20<br \/>12:40-13:40<\/td>\n<td style=\"width:122.07px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Guided Poster Session<\/td>\n<td style=\"width:94.54px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Poster Exhibition Hall A<\/td>\n<td style=\"width:89.2px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">P1159<\/td>\n<td style=\"width:168px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Pooled analysis of efficacy and safety of once-daily oral obefazimod in European patients from the ABTECT Phase 3 induction trials<\/td>\n<td style=\"width:145px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Prof. Franco Scaldaferri, MD, PhD<\/p>\n<p>Gastroenterologist, endoscopist<br \/>Director of the Chronic Inflammatory Bowel Diseases Unit, IBD UNIT<br \/>At the CEMAD UOC (Center for Digestive System Diseases)<\/p>\n<p>Gemelli Polyclinic Foundation IRCSS &#8211; Catholic University Of The Sacred Heart<\/p>\n<p>Dipartimento Di Medicina E Chirurgia Traslazionale, Universit\u00e0 Cattolica Del Sacro Cuore, Roma<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <br \/>\n        <b>About Abivax <\/b>\n      <\/p>\n<p align=\"justify\">Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body\u2019s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax\u2019s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.<\/p>\n<p align=\"justify\">\n        <b>Contact:<\/b><br \/>\n        <br \/>Patrick Malloy<br \/>SVP, Investor Relations<br \/>Abivax SA<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ynUKTgIK-9RVQ83MMCEb9u5foWjx-bU3NsRaKMCsmODa5-x-aGHjXOthISOKSAUV51sHKz7f9Mf6R_WARX-Jkdh6IR4sa5okFQ4mjaEExif7cunLoxfJWfnnYahg01a-\" rel=\"nofollow\" target=\"_blank\">patrick.malloy@abivax.com<\/a><br \/>+1 847 987 4878<\/p>\n<p align=\"justify\">\n        <b>Media Contact:<\/b><br \/>\n        <br \/>\n        <b>LifeSci Communications<\/b><br \/>\n        <br \/>Karissa Cross, Ph.D.<br \/>Account Supervisor<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=B-9bpFMO5qDhNpwj8D_biN4iGocXPZr8v5f6yMcXgN9IA3PihPzFbTWJzUkG9KvUcdADYgWClH1kooweYsal8ofYiokQqTgVXVQhxXz_WEAPR4hquwvWS2EThL1YOmJi\" rel=\"nofollow\" target=\"_blank\">kcross@lifescicomms.com<\/a><\/p>\n<p align=\"justify\">\n        <b><br \/>\n          <br \/>FORWARD-LOOKING STATEMENTS<\/b>\n      <\/p>\n<p align=\"justify\">\n        <i>This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company\u2019s business. Words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cpotential,\u201d \u201cwill\u201d and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning the Company\u2019s preclinical study results of obefazimod and the potential therapeutic benefit of obefazimod. Although Abivax\u2019s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorit\u00e9 des March\u00e9s Financiers pursuant to its legal obligations including its universal registration document (Document d\u2019Enregistrement Universel) and in its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 24, 2025 under the caption \u201cRisk Factors.\u201d These risks, contingencies and uncertainties include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, and the availability of funding sufficient for the Company\u2019s foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development, including further assessment by the Company and regulatory agencies and IRBs\/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell or the solicitation of an offer to purchase or subscribe for securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.<\/i>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0NTUxMSM0MDIyODUwNDUjMjAyMDExNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/YjEyMGJkODQtN2IwZi00MjgwLTg2YTYtNTljYTQ2NmJjN2QyLTEwMzE2ODktMjAyNS0xMi0xNy1lbg==\/tiny\/Abivax.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific Evidence: The acceptance of 1 oral presentation, 5 digital oral presentations and 16 posters reflect an expanding dataset for obefazimod, including additional efficacy, safety, and cytokine data from the Phase 3 ABTECT Induction Trials in moderate-to-severely active ulcerative colitis (UC) Novel Anti-Fibrotic Preclinical Findings: Oral presentation on Saturday, February 21, 2026, \u201cObefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease,&#8221; will disclose new preclinical data addressing a critical complication in Crohn&#8217;s disease (CD) PARIS, France \u2013 December 17, 2025 \u2013 10:05 pm CET \u2013 Abivax SA (Euronext Paris: FR0012333284 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-920717","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific Evidence: The acceptance of 1 oral presentation, 5 digital oral presentations and 16 posters reflect an expanding dataset for obefazimod, including additional efficacy, safety, and cytokine data from the Phase 3 ABTECT Induction Trials in moderate-to-severely active ulcerative colitis (UC) Novel Anti-Fibrotic Preclinical Findings: Oral presentation on Saturday, February 21, 2026, \u201cObefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease,&#8221; will disclose new preclinical data addressing a critical complication in Crohn&#8217;s disease (CD) PARIS, France \u2013 December 17, 2025 \u2013 10:05 pm CET \u2013 Abivax SA (Euronext Paris: FR0012333284 &hellip; Continue reading &quot;Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-17T21:24:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0NTUxMSM0MDIyODUwNDUjMjAyMDExNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings\",\"datePublished\":\"2025-12-17T21:24:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\\\/\"},\"wordCount\":2385,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE0NTUxMSM0MDIyODUwNDUjMjAyMDExNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\\\/\",\"name\":\"Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE0NTUxMSM0MDIyODUwNDUjMjAyMDExNw==\",\"datePublished\":\"2025-12-17T21:24:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE0NTUxMSM0MDIyODUwNDUjMjAyMDExNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTE0NTUxMSM0MDIyODUwNDUjMjAyMDExNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/","og_locale":"en_US","og_type":"article","og_title":"Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings - Market Newsdesk","og_description":"Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings Breadth of Scientific Evidence: The acceptance of 1 oral presentation, 5 digital oral presentations and 16 posters reflect an expanding dataset for obefazimod, including additional efficacy, safety, and cytokine data from the Phase 3 ABTECT Induction Trials in moderate-to-severely active ulcerative colitis (UC) Novel Anti-Fibrotic Preclinical Findings: Oral presentation on Saturday, February 21, 2026, \u201cObefazimod shows first evidence of anti-fibrotic activity in preclinical models of inflammatory bowel disease,&#8221; will disclose new preclinical data addressing a critical complication in Crohn&#8217;s disease (CD) PARIS, France \u2013 December 17, 2025 \u2013 10:05 pm CET \u2013 Abivax SA (Euronext Paris: FR0012333284 &hellip; Continue reading \"Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-17T21:24:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0NTUxMSM0MDIyODUwNDUjMjAyMDExNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings","datePublished":"2025-12-17T21:24:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/"},"wordCount":2385,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0NTUxMSM0MDIyODUwNDUjMjAyMDExNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/","name":"Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0NTUxMSM0MDIyODUwNDUjMjAyMDExNw==","datePublished":"2025-12-17T21:24:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0NTUxMSM0MDIyODUwNDUjMjAyMDExNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTE0NTUxMSM0MDIyODUwNDUjMjAyMDExNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abivax-announces-acceptance-of-22-abstracts-evaluating-obefazimod-in-inflammatory-bowel-disease-at-ecco-2026-featuring-an-oral-presentation-on-preclinical-anti-fibrotic-findings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/920717","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=920717"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/920717\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=920717"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=920717"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=920717"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}